Why Transdermal 2
SECUADO® provided smooth onset, steady delivery, and low peak-to-trough ratios3 Asenapine pharmacokinetics at steady state is dose-proportional in the dose range of 3.8 mg/24 hours to 7.6 mg/24 hours following application of the patch.1 Steady-state plasma concentrations are achieved in about 72 hours after the first application of SECUADO.1 Avoid exposing SECUADO® to direct external […]
Why Transdermal 1
SECUADO®, the first and only FDA-approved transdermal system for adults with schizophrenia: IT’S ON™ Why transdermal? When your patients with schizophrenia are ready for a change of treatment, the transdermal patch offers you the opportunity to change the conversation with a different treatment option. The SECUADO® patch is an option for your patients who: • […]
